<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256189</url>
  </required_header>
  <id_info>
    <org_study_id>300A</org_study_id>
    <nct_id>NCT02256189</nct_id>
  </id_info>
  <brief_title>Sitagliptin and Glucagon Counterregulation</brief_title>
  <acronym>SITACLAMP</acronym>
  <official_title>The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at
      moderate hypoglycemia in metformin-treated subjects with T2DM
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The glucagon response to mild (3.0 mmol/l) hypoglycemia with and without DPP-4 inhibition by
      sitagliptin will be evaluated in elderly subjects with metformin treated type 2 diabetes to
      explore whether DPP-4 inhibition affects glucagon counter-regulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon Counterregulation to Hypoglycemia</measure>
    <time_frame>Four weeks treatment</time_frame>
    <description>Change in plasma glucagon to insulin-induced hypoglycemia after four weeks of treatment with sitagliptin and placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sitagliptin first, then placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then sitagliptin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg daily</description>
    <arm_group_label>Sitagliptin first, then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo one tablet daily</description>
    <arm_group_label>Placebo first, then sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written consent has been given.

          2. Patients with metformin treated T2DM (metformin dose &gt;0,5 g/day and stable during the
             preceding 3 months)

          3. Age &gt;65 years.

          4. HbA1c 6.0-8.5% (43-67 mmol/mol; inclusive) at visit 1.

          5. Ability to complete the study

        Exclusion Criteria:

          1. A history of any secondary forms of diabetes, e.g., Cushing's syndrome and acromegaly.

          2. Type 2 diabetes, positive GAD antibodies

          3. eGFR &lt;60 ml/min

          4. Acute infections which may affect blood glucose control within 4 weeks prior to visit
             1

          5. Any history of recent (&lt;2 weeks) recurrent or severe hypoglycemic episodes.

          6. Liver disease such as cirrhosis or chronic active hepatitis

          7. History of coronary heart disease or heart failure class III or IV

          8. Donation of one unit (500 ml) or more of blood, significant blood loss equaling to at
             least one unit of blood within the past 2 weeks or a blood transfusion within the past
             8 weeks.

          9. Treatment with growth hormone of chronic oral or parenteral corticosteroid treatment
             (&gt; 7 consecutive days of treatment) within 8 weeks prior to visit 1.

         10. Use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable
             for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahrén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skane University Hospital Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <results_first_submitted>October 18, 2017</results_first_submitted>
  <results_first_submitted_qc>October 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2019</results_first_posted>
  <last_update_submitted>October 14, 2018</last_update_submitted>
  <last_update_submitted_qc>October 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02256189/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02256189/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin First, Then Placebo</title>
          <description>Sitagliptin first for four weeks, then washout for four weeks, then placebo for four weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Sitagliptin</title>
          <description>Placebo first for four weeks, then washout for four weeks, then placebo for four weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin First, Then Placebo</title>
          <description>Hypoglycemia clamp with sitagliptin
Sitagliptin: Treatment with sitagliptin 100mg QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Stagliptin</title>
          <description>Hypoglycemia clamp with placebo
Placebo: Treatment with placebo QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.0" spread="5.9"/>
                    <measurement group_id="B2" value="71.9" spread="5.7"/>
                    <measurement group_id="B3" value="73.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucagon</title>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="9.7"/>
                    <measurement group_id="B2" value="30.0" spread="12.2"/>
                    <measurement group_id="B3" value="29.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucagon Counterregulation to Hypoglycemia</title>
        <description>Change in plasma glucagon to insulin-induced hypoglycemia after four weeks of treatment with sitagliptin and placebo</description>
        <time_frame>Four weeks treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Hypoglycemia clamp with sitagliptin
Sitagliptin: Treatment with sitagliptin 100mg QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Hypoglycemia clamp with placebo
Placebo: Treatment with placebo QD for four weeks followed by hyperinsulinemic hypoglycemic clamp</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Counterregulation to Hypoglycemia</title>
          <description>Change in plasma glucagon to insulin-induced hypoglycemia after four weeks of treatment with sitagliptin and placebo</description>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="2.9"/>
                    <measurement group_id="O2" value="16.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin First, Then Placebo</title>
          <description>Sitagliptin first for four weeks, then washout for four weeks, then placebo for four weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then Stagliptin</title>
          <description>Placebo first for four weeks, then washout for four weeks, then sitalgiptin for four weeks</description>
        </group>
        <group group_id="E3">
          <title>Sitagliptin</title>
          <description>Sitagliptin 100mg Daily for four weeks, either before or after a 4 week placebo period</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo Daily for four weeks, efter before or after a 4 week sitagliptin period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Bo Ahrén</name_or_title>
      <organization>Lund University</organization>
      <phone>+46462220758</phone>
      <email>Bo.Ahren@med.lu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

